Lepu Biopharma Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Lepu Biopharma has been growing earnings at an average annual rate of 27.6%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 21.3% per year.
Anahtar bilgiler
27.6%
Kazanç büyüme oranı
44.5%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 11.0% |
| Gelir büyüme oranı | 21.3% |
| Özkaynak getirisi | -9.5% |
| Net Marj | -35.4% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Aug 23
The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%
Jul 18Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Jun 03Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%
Apr 15Gelir ve Gider Dağılımı
Lepu Biopharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 205 | -73 | 152 | 443 |
| 31 Mar 24 | 215 | -47 | 141 | 450 |
| 31 Dec 23 | 225 | -22 | 130 | 458 |
| 30 Sep 23 | 197 | -254 | 119 | 492 |
| 30 Jun 23 | 169 | -487 | 109 | 525 |
| 31 Mar 23 | 92 | -588 | 125 | 525 |
| 31 Dec 22 | 16 | -689 | 141 | 524 |
| 30 Sep 22 | 8 | -766 | 152 | 567 |
| 30 Jun 22 | 0 | -843 | 163 | 609 |
| 31 Mar 22 | 0 | -927 | 160 | 700 |
| 31 Dec 21 | 0 | -1,011 | 156 | 791 |
| 31 Dec 20 | 0 | -582 | 94 | 354 |
Kaliteli Kazançlar: 2157 is currently unprofitable.
Büyüyen Kar Marjı: 2157 is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 2157 is unprofitable, but has reduced losses over the past 5 years at a rate of 27.6% per year.
Büyüme Hızlandırma: Unable to compare 2157's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: 2157 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Özkaynak Getirisi
Yüksek ROE: 2157 has a negative Return on Equity (-9.46%), as it is currently unprofitable.